ecancer
@ecancer
ecancer is a charity with a mission to raise the standards of care for cancer patients across the world through education. #openaccess
ID: 19975787
https://www.ecancer.org 03-02-2009 15:03:46
21,21K Tweet
17,17K Followers
4,4K Following
The Phase 3 SURPASS-ET trial evaluates ropeginterferon alfa-2b versus anagrelide in patients with essential thrombocythaemia. Ropeginterferon shows superior safety and efficacy compared to anagrelide. Watch full interview with Dr Ruben Mesa here 👉 ecancer.org/en/video/12407… Ruben A. Mesa, MD
A cross-sectional analysis identified notable disparities in access to cancer screening among LGBTQ+ populations, particularly in mammogram utilisation. Dr Manas Pustake highlights the need for focused public health interventions 👇 ecancer.org/en/video/12409… Manas Pustake, MD
DYNAMIC-III study reveals that ctDNA-guided chemo escalation does not improve RFS in stage III colon cancer, compared to standard chemo. Full interview with Dr Jeanne Tie (Jeanne Tie) of Peter Mac Cancer Centre 👉 ecancer.org/en/video/12410… #ASCO25
Join us for an interactive seminar on 'Challenging the status quo: unlocking new horizons for patients with HR-NMIBC after BCG treatment' live from #UroOnco25. Register for free here 👉 ecancer.org/UroOnco25 #bladder #urology #Oncology Bernardo Herrera Imbroda Pignot Géraldine
Dr Maryam Lustberg (Maryam Lustberg MD, MPH, FASCO) highlights metastatic breast cancer research from #ASCO2025 👇 ecancer.org/en/video/12411… #ASCO25
Molecular subtypes and TOP1 gene expression may serve as predictive biomarkers of sacituzumab govitecan efficacy in MIBC: Dr Brigida Maiorano discusses the preliminary survival outcomes and biomarker analyses from SURE-01 👇 ecancer.org/en/video/12412… #ASCO25
Catequentinib improved median PFS to 3.42 months compared to 1.41 months with PBO (HR 0.54; p=0.0265). Results point to catequentinib as effective treatment option for pts with advanced or metastatic leiomyosarcoma. Interview with Robin Lewis Jones👇 ecancer.org/en/video/12413… #ASCO25
CheckMate 9ER: Findings highlight key tumour microenvironment and circulating biomarkers that can guide personalised therapy in advanced renal cell carcinoma. Watch the interview with Dr David Braun (David Braun) 👉 ecancer.org/en/video/12414… #ASCO25 Yale School of Medicine
HPK1 inhibitor NDI-101150 monotherapy shows safety profile and antitumour activity in patients with ccRCC. Dr David Braun (David Braun) talks about the results and what they suggest for renal cancer treatment 👉 ecancer.org/en/video/12415… #ASCO25 Yale School of Medicine
Neoadjuvant pembrolizumab + vidutolimod increases pathologic complete response rate in patients with resectable stage IIIB-D melanoma. Dr Ahmad Tarhini (Ahmad Tarhini) of Moffitt Research talks about the ECOG-ACRIN EA6194 trial 👇 ecancer.org/en/video/12416… #ASCO25
SWOG S2000 – a randomised phase-2 trial in pts with symptomatic melanoma brain metastases: Triple regimen shows improvement in PFS & higher response rates compared to standard ipi/nivo. Interview with Dr Zeynep Eroglu of Moffitt Research 👉 ecancer.org/en/video/12417… #ASCO25
We welcome you to register for the 9th Tata Annual Biostatistics and Research Methodology Course. Registration: tmckolkata.com/in/biostatisti… SIOP International Country Ambassador for India Pritam Singha Roy reflects on his experience of attending the research. Association for Child & Adolescent Mental Health ecancer
Dr Kunvar Harsh Upveja discusses the cost and logistical implications of IV versus SC trastuzumab in HER2+ breast cancer patients in Morocco. Full interview here ecancer.org/en/video/12418… #ASCO25 Biocon Biologics
🚀 First steps in co-creation! We held our first iBeChange focus group at ICO (Institut Català d'Oncologia) to gather real user insights on making the app more engaging & effective. Real feedback = real impact. #iBeChange #DigitalHealth #CoCreation #mHealth
